{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T07:15:09Z","timestamp":1765782909976,"version":"3.48.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Adalimumab and ustekinumab are approved for the treatment of moderately to severely active Crohn\u2019s disease (CD); however, comparative data assessing the mechanism of action of tumor necrosis factor (TNF\u03b1) and interleukin (IL)-12\/23p40 blockade in a head-to-head, double-blind CD trial are not available. Here we compared inflammatory serum proteins of biologic-naive patients with moderately to severely active CD treated with adalimumab or ustekinumab who participated in the SEAVUE trial (NCT03464136).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Serum from CD patients receiving adalimumab (n\u2009=\u2009195) or ustekinumab (n\u2009=\u2009191), and from a separate cohort of healthy controls (n\u2009=\u200940) was evaluated with a targeted inflammation panel, and a high sensitivity IL-22 assay. Differences in temporally regulated proteins were assessed at Weeks 16 and 52 in the context of study endpoints including clinical and endoscopic response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Expression levels of 79 inflammatory proteins were reliably measured in serum. At Week 0, before receiving study intervention, the overall cohort had similar serum proteomic expression profiles. At Weeks 16 and 52, following treatment with adalimumab or ustekinumab, distinct changes in serum proteins associated with inflammation were observed, including broader suppression of inflammation-related proteins by adalimumab and a reduction of IL-22 observed only with ustekinumab. Reduction of interferon-\u03b3 levels by ustekinumab at Week 52 was greater than by adalimumab and associated with a decrease in fatigue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although patients receiving either adalimumab or ustekinumab reached similar rates of clinical remission at Week 52, the two therapies resulted in unique serum proteomic expression profiles, reflecting mechanistic differences. Long-term treatment data are necessary to understand how differences in therapeutic mechanisms are associated with maintenance of remission and changes in patient-reported outcomes in the context of inflammatory biomarkers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf197","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:49:08Z","timestamp":1763470148000},"source":"Crossref","is-referenced-by-count":0,"title":["Serum protein profiles differ with adalimumab and ustekinumab treatment in moderately to severely active Crohn\u2019s disease"],"prefix":"10.1093","volume":"19","author":[{"given":"Swati","family":"Venkat","sequence":"first","affiliation":[{"name":"Research and Development, Johnson & Johnson , Spring House, PA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Zeeman","sequence":"additional","affiliation":[{"name":"Research and Development, Johnson & Johnson , Spring House, PA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Hart","sequence":"additional","affiliation":[{"name":"Research and Development, Johnson & Johnson , Spring House, PA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita","family":"Bhagat","sequence":"additional","affiliation":[{"name":"Research and Development, Johnson & Johnson , Spring House, PA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A","family":"Galbraith","sequence":"additional","affiliation":[{"name":"Research and Development, Johnson & Johnson , Spring House, PA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Hoops","sequence":"additional","affiliation":[{"name":"Medical Affairs, Johnson & Johnson , Horsham, PA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J","family":"Ufberg","sequence":"additional","affiliation":[{"name":"Research and Development, Johnson & Johnson , Spring House, PA,","place":["United States"]},{"name":"Medical Affairs, Johnson & Johnson Formerly of , Horsham, PA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Izanec","sequence":"additional","affiliation":[{"name":"Medical Affairs, Johnson & Johnson Formerly of , Horsham, PA,","place":["United States"]},{"name":"Clinical Development, Bristol Myers Squibb Current affiliation: , Princeton, NJ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom C","family":"Freeman","sequence":"additional","affiliation":[{"name":"Immunology, Johnson & Johnson Formerly of , Spring House, PA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradford","family":"Mcrae","sequence":"additional","affiliation":[{"name":"Research and Development, Johnson & Johnson , Spring House, PA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7051-618X","authenticated-orcid":false,"given":"Shinichiro","family":"Shinzaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hyogo Medical University School of Medicine , Hyogo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-0033","authenticated-orcid":false,"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, University Hospital , London, ON,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5247-940X","authenticated-orcid":false,"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary , Calgary, AB,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce E","family":"Sands","sequence":"additional","affiliation":[{"name":"The Dr Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9741-9067","authenticated-orcid":false,"given":"Patrick","family":"Branigan","sequence":"additional","affiliation":[{"name":"Research and Development, Johnson & Johnson , Spring House, PA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"year":"2021","author":"Humira (adalimumab) prescribing information","key":"2025121502120543800_jjaf197-B1"},{"year":"2020","author":"Stelara (ustekinumab) prescribing information","key":"2025121502120543800_jjaf197-B2"},{"key":"2025121502120543800_jjaf197-B3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"2025121502120543800_jjaf197-B4","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"2025121502120543800_jjaf197-B5","first-page":"1329","article-title":"Briakinumab for treatment of Crohn\u2019s disease: results of a randomized trial","volume":"21","author":"Panaccione","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2025121502120543800_jjaf197-B6","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"2025121502120543800_jjaf197-B7","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of action of anti-TNF therapy in inflammatory bowel disease","volume":"10","author":"Levin","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2025121502120543800_jjaf197-B8","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain","volume":"421","author":"Cua","year":"2003","journal-title":"Nature"},{"key":"2025121502120543800_jjaf197-B9","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.immuni.2015.09.003","article-title":"Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability","volume":"43","author":"Lee","year":"2015","journal-title":"Immunity"},{"key":"2025121502120543800_jjaf197-B10","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.immuni.2015.08.019","article-title":"Differential roles for Interleukin-23 and Interleukin-17 in intestinal immunoregulation","volume":"43","author":"Maxwell","year":"2015","journal-title":"Immunity"},{"key":"2025121502120543800_jjaf197-B11","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat Med"},{"key":"2025121502120543800_jjaf197-B12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","article-title":"IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting","volume":"16","author":"Moschen","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025121502120543800_jjaf197-B13","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1159\/000518103","article-title":"Ustekinumab improves active Crohn\u2019s disease by suppressing the T helper 17 pathway","volume":"102","author":"Ihara","year":"2021","journal-title":"Digestion"},{"key":"2025121502120543800_jjaf197-B14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025121502120543800_jjaf197-B15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/apt.13001","article-title":"A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn\u2019s disease activity","volume":"41","author":"Khanna","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121502120543800_jjaf197-B16","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.MIB.0000173271.18319.53","article-title":"Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease","volume":"11","author":"Solem","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"2025121502120543800_jjaf197-B17","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/ajg.2009.454","article-title":"Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn\u2019s disease","volume":"104","author":"Toedter","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"2025121502120543800_jjaf197-B18","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2036.2011.04987.x","article-title":"C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn\u2019s disease: a post-hoc analysis from ACCENT I","volume":"35","author":"Reinisch","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121502120543800_jjaf197-B19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1155\/2015\/389548","article-title":"Biomarkers as potential treatment targets in inflammatory bowel disease: a systematic review","volume":"29","author":"Murdoch","year":"2015","journal-title":"Can J Gastroenterol Hepatol"},{"key":"2025121502120543800_jjaf197-B20","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/ibd\/izae016","article-title":"Crohn\u2019s patient serum proteomics reveals response signature for infliximab but not vedolizumab","volume":"30","author":"Gonzalez","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2025121502120543800_jjaf197-B21","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.mucimm.2024.09.004","article-title":"Combined plasma protein and memory T cell profiling discern IBD-patient-immunotypes related to intestinal disease and treatment outcomes","volume":"18","author":"Heredia","year":"2025","journal-title":"Mucosal Immunol"},{"key":"2025121502120543800_jjaf197-B22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.gastro.2017.03.049","article-title":"Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn\u2019s disease: a phase 2a study","volume":"153","author":"Sands","year":"2017","journal-title":"Gastroenterology"},{"key":"2025121502120543800_jjaf197-B23","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1007\/s10620-024-08421-w","article-title":"Correlation between plasma and fecal biomarkers and patient-reported outcomes in patients with Crohn\u2019s disease and ulcerative colitis","volume":"69","author":"Motwani","year":"2024","journal-title":"Dig Dis Sci"},{"key":"2025121502120543800_jjaf197-B24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/CEG.S123942","article-title":"Fatigue in patients with inflammatory bowel disease is associated with distinct differences in immune parameters","volume":"10","author":"Vogelaar","year":"2017","journal-title":"Clin Exp Gastroenterol"},{"key":"2025121502120543800_jjaf197-B25","doi-asserted-by":"crossref","first-page":"e076290","DOI":"10.1136\/bmjopen-2023-076290","article-title":"Predicting mucosal inflammation in IBD patients using patient-reported symptom scores and a faecal calprotectin home test: protocol for a multicentre prospective validation study","volume":"14","author":"Janssen","year":"2024","journal-title":"BMJ Open"},{"key":"2025121502120543800_jjaf197-B26","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet"},{"key":"2025121502120543800_jjaf197-B27","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1016\/j.jid.2019.05.016","article-title":"Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-Regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study","volume":"139","author":"Gordon","year":"2019","journal-title":"J Invest Dermatol"},{"volume-title":"R: A Language and Environment for Statistical Computing","year":"2025","author":"R Core Team","key":"2025121502120543800_jjaf197-B28"},{"key":"2025121502120543800_jjaf197-B29","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/bioinformatics\/btaa687","article-title":"Dream: powerful differential expression analysis for repeated measures designs","volume":"37","author":"Hoffman","year":"2021","journal-title":"Bioinformatics"},{"key":"2025121502120543800_jjaf197-B30","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jval.2024.05.019","article-title":"Qualitative and psychometric evaluation of 29-Item Patient-Reported Outcomes Measurement Information System\u00ae to assess general health-related quality of life in patients with moderately to severely active inflammatory bowel disease","volume":"27","author":"Sands","year":"2024","journal-title":"Value Health"},{"key":"2025121502120543800_jjaf197-B31","doi-asserted-by":"crossref","first-page":"G827","DOI":"10.1152\/ajpgi.00513.2005","article-title":"IL-22 is increased in active Crohn\u2019s disease and promotes proinflammatory gene expression and intestinal epithelial cell migration","volume":"290","author":"Brand","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2025121502120543800_jjaf197-B32","doi-asserted-by":"crossref","first-page":"e20192195","DOI":"10.1084\/jem.20192195","article-title":"The role of IL-22 in intestinal health and disease","volume":"217","author":"Keir","year":"2020","journal-title":"J Exp Med"},{"key":"2025121502120543800_jjaf197-B33","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1038\/s41467-022-33331-8","article-title":"Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy","volume":"13","author":"Pavlidis","year":"2022","journal-title":"Nat Commun"},{"key":"2025121502120543800_jjaf197-B34","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1111\/febs.14466","article-title":"A guide to chemokines and their receptors","volume":"285","author":"Hughes","year":"2018","journal-title":"Febs J"},{"key":"2025121502120543800_jjaf197-B35","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/ecco-jcc\/jjy130","article-title":"Chemokines and chemokine receptors as therapeutic targets in inflammatory bowel disease; pitfalls and promise","volume-title":"J Crohns Colitis","author":"Trivedi","year":"2018"},{"key":"2025121502120543800_jjaf197-B36","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1093\/ibd\/izaa301","article-title":"Histologic remission is associated with lower risk of treatment failure in patients with Crohn disease in endoscopic remission","volume":"27","author":"Yoon","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2025121502120543800_jjaf197-B37","doi-asserted-by":"crossref","first-page":"6966","DOI":"10.3390\/ijms23136966","article-title":"Inflammatory bowel disease treatments and predictive biomarkers of therapeutic response","volume":"23","author":"Elhag","year":"2022","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf197\/65394847\/jjaf197.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/11\/jjaf197\/65394847\/jjaf197.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/11\/jjaf197\/65394847\/jjaf197.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T07:12:25Z","timestamp":1765782745000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf197\/8328035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf197","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"type":"print","value":"1873-9946"},{"type":"electronic","value":"1876-4479"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,11]]},"article-number":"jjaf197"}}